TY - JOUR
T1 - Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?
AU - Klaassen, Zachary
AU - Howard, Lauren
AU - Wallis, Christopher J.D.
AU - Janes, Jessica L.
AU - De Hoedt, Amanda
AU - Aronson, William J.
AU - Polascik, Thomas J.
AU - Amling, Christopher J.
AU - Kane, Christopher J.
AU - Cooperberg, Matthew R.
AU - Terris, Martha K.
AU - Wu, Yuan
AU - Freedland, Stephen J.
N1 - Funding Information:
This work was supported by funding from Pfizer. Furthermore, additional support included NIH R01CA231219 (WJA), and the Georgia Cancer Coalition (MKT). Views and opinions of, and endorsements by the author(s), do not reflect those of the US Army or the Dept. of Defense.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2023/3
Y1 - 2023/3
N2 - Purpose: Metastasis-free survival (MFS) is a surrogate for overall survival (OS) in men with non-metastatic castration-resistant prostate cancer (CRPC), but this endpoint may take years to develop in men with non-metastatic castrate-sensitive disease. The study objective was to examine whether progression to CRPC is a potential intermediate endpoint for developing metastatic disease in patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Materials and methods: Men with BCR following RP who had PSA doubling times (PSADT) < 9 months and no metastasis at the time of initiating androgen deprivation therapy (ADT) (n = 210) were included. The primary objective was to assess the correlation between CRPC-free survival (CRPC-FS) and MFS, and the secondary objective was to assess the correlation between time to metastasis and time to CRPC. Kendall’s Tau was used to test the correlation for the primary and secondary outcomes. Results: The median MFS was 104 months (95% CI: 83–114) and median CRPC-FS was 100 months (95% CI: 80–114). Based on the Kaplan–Meier curve, the greatest difference in time to MFS and CRPC-FS was around 70% free survival, which was reached at 61.2 months for MFS and 49.6 months for CRPC-FS. Kendall’s Tau for the correlation between CRPC-FS and MFS and between time to CRPC and time to metastasis was 0.867 (95% CI: 0.765–0.968) and 0.764 (95% CI: 0.644–0.884), respectively. Conclusions: Given the high correlation between CRPC-FS and MFS, after validation, CRPC-FS may serve as a potential intermediate endpoint in trials for men with BCR initiating ADT following local therapy.
AB - Purpose: Metastasis-free survival (MFS) is a surrogate for overall survival (OS) in men with non-metastatic castration-resistant prostate cancer (CRPC), but this endpoint may take years to develop in men with non-metastatic castrate-sensitive disease. The study objective was to examine whether progression to CRPC is a potential intermediate endpoint for developing metastatic disease in patients with biochemical recurrence (BCR) after radical prostatectomy (RP). Materials and methods: Men with BCR following RP who had PSA doubling times (PSADT) < 9 months and no metastasis at the time of initiating androgen deprivation therapy (ADT) (n = 210) were included. The primary objective was to assess the correlation between CRPC-free survival (CRPC-FS) and MFS, and the secondary objective was to assess the correlation between time to metastasis and time to CRPC. Kendall’s Tau was used to test the correlation for the primary and secondary outcomes. Results: The median MFS was 104 months (95% CI: 83–114) and median CRPC-FS was 100 months (95% CI: 80–114). Based on the Kaplan–Meier curve, the greatest difference in time to MFS and CRPC-FS was around 70% free survival, which was reached at 61.2 months for MFS and 49.6 months for CRPC-FS. Kendall’s Tau for the correlation between CRPC-FS and MFS and between time to CRPC and time to metastasis was 0.867 (95% CI: 0.765–0.968) and 0.764 (95% CI: 0.644–0.884), respectively. Conclusions: Given the high correlation between CRPC-FS and MFS, after validation, CRPC-FS may serve as a potential intermediate endpoint in trials for men with BCR initiating ADT following local therapy.
UR - http://www.scopus.com/inward/record.url?scp=85137230983&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137230983&partnerID=8YFLogxK
U2 - 10.1038/s41391-022-00585-8
DO - 10.1038/s41391-022-00585-8
M3 - Article
C2 - 36050455
AN - SCOPUS:85137230983
SN - 1365-7852
VL - 26
SP - 151
EP - 155
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 1
ER -
